Antimicrobial resistance: Concerns of healthcare providers and people with CF

  18 June 2020

Chronic lung infections and their treatment pose risks for the development of antimicrobial resistance (AMR) in people with cystic fibrosis (PWCF). In this study, we evaluated the attitudes of healthcare providers’ (HCP) and PWCF or their parents’ toward AMR within the international CF community.

These results highlight that AMR is relevant to CF HCP and PWCF internationally, indicating that educational tools and research are warranted.

Author(s): Wendy Bullington, Sarah Hempstead, Alan R. Smyth, Pavel Drevinek, Lisa Saiman, Valerie J. Waters, Scott C. Bell, Donald R. Van Devanter, Patrick A. Flume, Stuart Elborn, Marianne S Muhlebach
Healthy Patients  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Evotec

JSS University

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!